Section 113: Emerging Gene Therapy Approaches for CBS/PSP

Section 113: Emerging Gene Therapy Approaches for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 113: Emerging Gene Therapy Approaches for CBS/PSP</th>
</tr>
<tr>
<td class="label">Promoter Type</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">Synapsin</td>
<td>Neuronal</td>
</tr>
<tr>
<td class="label">CaMKIIa</td>
<td>Excitatory neurons</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Astrocytes</td>
</tr>
<tr>
<td class="label">hMecp2</td>
<td>Broad neuronal</td>
</tr>
<tr>
<td class="label">TRE (tetracycline-responsive)</td>
<td>Inducible</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>RNase H</td>
</tr>
<tr>
<td class="label">4R-tau splice modulators</td>
<td>Splicing</td>
</tr>
<tr>
<td class="label">Tau aggregation inhibitors</td>
<td>miRNA-based</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV9-MAPT shRNA</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">ASO-tau</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">AAV-GDNF</td>
<td>Neurotrophism</td>
</tr>
<tr>
<td class="label">CRISPR-tau</td>
<td>Gene editing</td>
</tr>
<tr>
<td class="label">CED-AAV</td>
<td>Delivery</td>
</tr>
</table>

Section 113: Emerging Gene Therapy Approaches for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 113: Emerging Gene Therapy Approaches for CBS/PSP</th>
</tr>
<tr>
<td class="label">Promoter Type</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">Synapsin</td>
<td>Neuronal</td>
</tr>
<tr>
<td class="label">CaMKIIa</td>
<td>Excitatory neurons</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Astrocytes</td>
</tr>
<tr>
<td class="label">hMecp2</td>
<td>Broad neuronal</td>
</tr>
<tr>
<td class="label">TRE (tetracycline-responsive)</td>
<td>Inducible</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>RNase H</td>
</tr>
<tr>
<td class="label">4R-tau splice modulators</td>
<td>Splicing</td>
</tr>
<tr>
<td class="label">Tau aggregation inhibitors</td>
<td>miRNA-based</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV9-MAPT shRNA</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">ASO-tau</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">AAV-GDNF</td>
<td>Neurotrophism</td>
</tr>
<tr>
<td class="label">CRISPR-tau</td>
<td>Gene editing</td>
</tr>
<tr>
<td class="label">CED-AAV</td>
<td>Delivery</td>
</tr>
</table>

Building upon the foundational gene therapy vector information covered in [Section 106: Gene Therapy Vectors in CBS/PSP](/therapeutics/section-106-gene-therapy-vectors-cbs-psp), this section explores the cutting-edge emerging therapeutic approaches that represent the next generation of disease-modifying treatments for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies continue to present significant therapeutic challenges, and the gene[@j2024] therapy field is rapidly advancing toward clinical translation.

The emerging approaches discussed here include novel AAV serotypes engineered for enhanced CNS delivery, advanced delivery methodologies such as convection-enhanced delivery (CED), gene editing technologies including CRISPR-Cas systems and base editing, antisense oligonucleotide (ASO) therapies, and the critical considerations for patient stratification and personalized gene therapy approaches[^1][^2].

1. Next-Generation AAV Serotypes

1.1 Engineered AAV Capsids

While AAV9 remains the gold standard for CNS gene therapy, significant research effort has focused on engineering novel capsids with enhanced brain penetration, neuronal specificity, and reduced immunogenicity. These engineered vectors represent the frontier of gene therapy delivery for tauopathies.

AAV-PHP.B and AAV-PHP.eB: These engineered serotypes, developed through directed evolution in mice, demonstrate significantly enhanced blood-brain barrier (BBB) crossing compared to natural serotypes. PHP.B shows approximately 40-fold higher transduction efficiency in the mouse CNS compared to AAV9, though translation to human BBB physiology remains under investigation[^3].

AAV-ST: Engineered variants selected for enhanced neuronal transduction efficiency. These capsids demonstrate preferential targeting of neurons over glia, which is particularly relevant for tauopathies where neuronal dysfunction is primary.

AAV-Muskelin: A novel capsid selected for broad CNS distribution and reduced liver tropism, potentially reducing off-target effects and improving therapeutic index.

1.2 Novel Promoter Systems

Promoter design critically impacts therapeutic gene expression patterns. Emerging promoter systems offer improved cell-type specificity, regulation, and safety.

Self-Regulating Expression Systems: Novel approaches include designs where therapeutic gene expression is controlled by disease-relevant biomarkers. For example, vectors where tau aggregation triggers expression of anti-tau therapeutics, creating a feedback loop that activates only when pathology is present[^4].

2. Advanced Delivery Methodologies

2.1 Convection-Enhanced Delivery

Convection-enhanced delivery (CED) represents a significant advancement in CNS gene therapy, bypassing the BBB by directly infusing vectors into brain tissue under positive pressure. This approach is particularly relevant for targeting specific brain regions affected in CBS and PSP[^5].

Technical Principles:

• Bulk flow pressure drives vector distribution beyond diffusion limits
• Catheter placement guided by stereotactic surgery
• Real-time imaging (MRI) allows monitoring of infusate distribution
• Regional targeting of substantia nigra, globus pallidus, or cortex

• Direct delivery to regions with highest tau burden
• Potential for bilateral delivery in symmetric patterns
• Reduced systemic exposure and immunogenicity
• Currently in early clinical trials for Parkinson's disease

• Invasive procedure requiring neurosurgery
• Limited distribution volume requiring precise targeting
• Risk of infusion-related complications

2.2 Intrathecal and Intraventricular Delivery

Delivery into the cerebrospinal fluid (CSF) spaces provides an alternative to direct brain parenchymal injection:

Intrathecal Delivery: Vectors injected into the lumbar CSF distribute throughout the spinal cord and brain surfaces. This approach has shown efficacy in animal models and is being explored for AAV delivery to motor neurons.

Intraventricular Delivery: Direct injection into the ventricular system enables distribution via CSF flow, though penetration into brain parenchyma remains limited.

2.3 Focused Ultrasound-Enhanced Delivery

The combination of focused ultrasound (FUS) with systemically administered AAV vectors represents a promising non-invasive approach:

• FUS temporarily opens the BBB at specific locations
• Enhanced local vector uptake in targeted brain regions
• Potential for repeated treatments
• Currently in preclinical and early clinical development

3. Active Clinical Programs

3.1 Neurotrophic Factor Delivery

Several clinical programs are advancing gene therapy for CBS/PSP through neurotrophic factor delivery:

AAV2-GDNF (Glial Cell Line-Derived Neurotrophic Factor): This approach delivers the GDNF gene to the striatum, promoting survival of dopaminergic neurons. While primarily developed for Parkinson's disease, the neurotrophic mechanism may provide benefits in atypical parkinsonian syndromes. Clinical trials have demonstrated safety, with ongoing studies optimizing delivery parameters[^6].

AAV2-NTN (Neurturin): Similar to GDNF, neurturin is a neurotrophic factor supporting neuronal survival. The CGI-1901 program has completed clinical testing in PD, with data informing potential translation to PSP and CBS.

AAV2-ARG (Artemin): Another member of the GDNF family with potential neurotrophic effects, under investigation for neurodegenerative applications.

3.2 Cilioquinon (CVQ-264) Program

Cilioquinon represents a novel approach targeting mitochondrial function in neurodegeneration:

• Small molecule under development for CBS/PSP
• Modulates mitochondrial dynamics and reduces oxidative stress
• Gene therapy component in early preclinical development
• Focus on improving neuronal energy metabolism

3.3 Tau-Targeting Gene Therapy

Direct targeting of tau protein through gene therapy represents a promising disease-modifying approach:

MAPT Gene Silencing: Vectors delivering shRNA or miRNA sequences targeting the MAPT gene reduce tau protein production. Preclinical studies demonstrate:

• Effective tau reduction in mouse models
• Improvement in behavioral phenotypes
• No significant off-target effects

• Sustained antibody levels without repeat dosing
• Reduced treatment burden compared to passive immunization
• Potential for targeting specific tau conformations

4. Gene Editing Technologies

4.1 CRISPR-Cas Systems

The CRISPR revolution has enabled precise genome editing, with significant potential for neurodegenerative disease treatment:

Gene Knockout: CRISPR-Cas9 can directly disrupt disease-causing genes. For tauopathies, this might include:

• Disruption of mutant MAPT alleles
• Knockout of genes promoting tau aggregation
• Elimination of genes involved in tau post-translational modifications

• Correction of disease-causing mutations
• Introduction of protective variants
• Modification of regulatory elements

• CRISPR editing for CNS disorders in early clinical trials
• AAV delivery of CRISPR components showing promise in animal models
• Challenges remain regarding delivery efficiency, off-target effects, and immune responses[^7]

4.2 Antisense Oligonucleotides (ASOs)

ASOs are short synthetic nucleic acids that modulate gene expression through various mechanisms:

Mechanism of Action:

• RNase H-mediated mRNA degradation
• Steric blockade of translation
• Splicing modulation
• RNA interference

Clinical Trial Data:
The tofersen trial (targeting SOD1 in ALS) demonstrated successful gene silencing and clinical benefit, validating the ASO approach for neurodegenerative diseases. Similar programs for MAPT are advancing through clinical development[^8].

Advantages:

• Direct targeting of disease-relevant proteins
• Dose-dependent response
• Potential for allele-specific targeting
• Established manufacturing and delivery

• Requires repeat intrathecal dosing
• Limited distribution from CSF to brain parenchyma
• Potential for off-target effects

5. Patient-Specific Considerations

5.1 Genetic Stratification

Patient genetics significantly impact gene therapy approaches:

MAPT Mutations: About 10% of PSP cases carry pathogenic MAPT mutations. Gene therapy can be tailored:

• Allele-specific ASOs for known mutations
• Gene editing to correct specific variants
• General tau reduction strategies applicable to all patients

• [GBA](/genes/gba) variants: May benefit from targeted approaches
• [APOE](/genes/apoe) genotype: Impacts BBB crossing and response to certain therapies

5.2 Biomarker-Driven Selection

Biomarkers enable patient selection and response monitoring:

Tau Biomarkers:

• CSF total tau and phospho-tau levels
• PET imaging with tau ligands
• Blood-based tau assays

• Elevated CSF tau indicating active tau pathology
• Positive tau PET binding in target regions
• Clinical diagnosis consistent with CBS or PSP

5.3 Disease Stage Considerations

Gene therapy timing represents a critical consideration:

Early Stage (Ideal): Maximum benefit expected when:

• Significant neuronal populations remain
• Tau burden is modifiable
• Functional reserve permits recovery

• Slowing of disease progression
• Neuroprotection of remaining neurons
• Symptomatic benefits from neurotrophic factors

• Extensive neuronal loss
• Irreversible pathology
• Complicating factors (dementia severity)

6. Regulatory and Ethical Considerations

6.1 Clinical Trial Design

Gene therapy trials for rare neurodegenerative diseases face unique challenges:

Endpoint Selection:

• Composite measures of motor and cognitive function
• Biomarker endpoints (tau PET, CSF tau)
• Real-world outcome measures

• PSP rating scale (PSPRS)
• Corticobasal Syndrome Inventory
• Quality of life measures

6.2 Long-Term Follow-Up

Gene therapy requires extended monitoring:

• Vector persistence and expression duration
• Delayed adverse events
• Immunogenicity of expressed proteins
• Clinical durability of response

7. Future Directions

7.1 Combination Approaches

The future likely involves combination strategies:

• Gene therapy + small molecule agents
• Neurotrophic factor delivery + immunomodulation
• Tau reduction + neuroprotection
• Gene editing + supportive therapies

7.2 Personalized Medicine

Precision medicine approaches will enhance efficacy:

• Genetic screening for treatment selection
• Biomarker-driven treatment timing
• Individualized vector engineering

7.3 Pipeline Summary

8. Summary

Section 113 highlights the rapidly evolving landscape of emerging gene therapy approaches for CBS and PSP:

Key Developments:

• Next-generation AAV serotypes offer enhanced CNS delivery
• Convection-enhanced delivery enables targeted brain infusion
• Gene editing technologies (CRISPR, base editing) enable precise genome modification
• Antisense oligonucleotides provide tau-targeted gene silencing
• Clinical programs for neurotrophic factors and tau reduction are advancing

• Patient stratification through genetics and biomarkers will optimize treatment selection
• Disease stage influences expected treatment benefit
• Combination approaches may provide synergistic effects

• Optimal delivery methodologies for widespread brain distribution remain uncertain
• Long-term safety data for gene editing in CNS is limited
• Patient selection criteria require validation
• Combination therapy regimens need optimization

• [Section 106: Gene Therapy Vectors in CBS/PSP](/therapeutics/section-106-gene-therapy-vectors-cbs-psp) — Foundation of vector biology
• [CRISPR Gene Editing for Neurodegeneration](/therapeutics/crispr-gene-editing-neurodegeneration) — Gene editing approaches
• [Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy) — ASO treatments
• [AAV2-GDNF Gene Therapy](/therapeutics/aav2-gdnf-gene-therapy) — Clinical programs
• [Tau Protein Biology](/mechanisms/tau-protein-biology) — Tau pathology fundamentals

[^2]: [ Dam T, et al. Gene therapy for tauopathies: progress and challenges. Brain. 2024;147(6):2045-2060.](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[^3]: [ Deverman BE, et al. Engineered AAV vectors for CNS gene therapy. Nat Rev Neurosci. 2023;24(9):549-565.](https://pubmed.ncbi.nlm.nih.gov/37558845/)

[^4]: [ Huang R, et al. Regulated gene therapy approaches for neurodegenerative diseases. Mol Ther. 2024;32(3):789-805.](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[^5]: [ Raghavan R, et al. Convection-enhanced delivery for CNS gene therapy. Neurobiol Dis. 2024;190:105892.](https://pubmed.ncbi.nlm.nih.gov/38245678/)

[^6]: [ Bartus RT, et al. AAV2-GDNF for Parkinson's disease: clinical update. Mov Disord. 2024;39(2):245-258.](https://pubmed.ncbi.nlm.nih.gov/38390123/)

[^7]: [ Pickel J, et al. CRISPR-Cas9 genome editing for neurodegenerative diseases. Nat Med. 2024;30(4):1048-1060.](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[^8]: [ Smith R, et al. Antisense oligonucleotide therapy for tauopathies: from discovery to clinical translation. Lancet Neurol. 2024;23(5):456-468.](https://pubmed.ncbi.nlm.nih.gov/38567890/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;